Last reviewed · How we verify
Bevacizumab and Pemetrexed/platinum
Bevacizumab and Pemetrexed/platinum is a Combination therapy: monoclonal antibody (anti-VEGF) + antifolate + platinum chemotherapy Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Non-small cell lung cancer (phase 3 trial).
This combination uses bevacizumab to inhibit tumor blood vessel formation while pemetrexed and platinum chemotherapy directly kill cancer cells.
This combination uses bevacizumab to inhibit tumor blood vessel formation while pemetrexed and platinum chemotherapy directly kill cancer cells. Used for Non-small cell lung cancer (phase 3 trial).
At a glance
| Generic name | Bevacizumab and Pemetrexed/platinum |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Combination therapy: monoclonal antibody (anti-VEGF) + antifolate + platinum chemotherapy |
| Target | VEGF (bevacizumab); thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (platinum) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a monoclonal antibody that blocks VEGF signaling to prevent angiogenesis and starve tumors of blood supply. Pemetrexed is an antifolate that inhibits multiple enzymes in nucleotide synthesis, and platinum agents (cisplatin or carboplatin) cause DNA crosslinking and cell death. Together, the anti-angiogenic and cytotoxic mechanisms target tumor growth through complementary pathways.
Approved indications
- Non-small cell lung cancer (phase 3 trial)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Fatigue
- Bleeding
- Hypertension
- Proteinuria
Key clinical trials
- SYS6090 Combination Therapy in Advanced Lung Cancer (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs (PHASE2)
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (PHASE1)
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bevacizumab and Pemetrexed/platinum CI brief — competitive landscape report
- Bevacizumab and Pemetrexed/platinum updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Bevacizumab and Pemetrexed/platinum
What is Bevacizumab and Pemetrexed/platinum?
How does Bevacizumab and Pemetrexed/platinum work?
What is Bevacizumab and Pemetrexed/platinum used for?
Who makes Bevacizumab and Pemetrexed/platinum?
What drug class is Bevacizumab and Pemetrexed/platinum in?
What development phase is Bevacizumab and Pemetrexed/platinum in?
What are the side effects of Bevacizumab and Pemetrexed/platinum?
What does Bevacizumab and Pemetrexed/platinum target?
Related
- Drug class: All Combination therapy: monoclonal antibody (anti-VEGF) + antifolate + platinum chemotherapy drugs
- Target: All drugs targeting VEGF (bevacizumab); thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase (pemetrexed); DNA (platinum)
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer (phase 3 trial)
- Compare: Bevacizumab and Pemetrexed/platinum vs similar drugs
- Pricing: Bevacizumab and Pemetrexed/platinum cost, discount & access